CX3CR1 identifies PD-1 therapy–responsive CD8(+) T cells that withstand chemotherapy during cancer chemoimmunotherapy

Although immune checkpoint inhibitors have resulted in durable clinical benefits in a subset of patients with advanced cancer, some patients who did not respond to initial anti–PD-1 therapy have been found to benefit from the addition of salvage chemotherapy. However, the mechanism responsible for t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCI Insight
Main Authors: Yan, Yiyi, Cao, Siyu, Liu, Xin, Harrington, Susan M., Bindeman, Wendy E., Adjei, Alex A., Jang, Jin Sung, Jen, Jin, Li, Ying, Chanana, Pritha, Mansfield, Aaron S., Park, Sean S., Markovic, Svetomir N., Dronca, Roxana S., Dong, Haidong
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5931117/
https://ncbi.nlm.nih.gov/pubmed/29669928
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.97828
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados